Viela Bio, Inc

(NASDAQ:VIE)

Latest On Viela Bio, Inc (VIE):

Date/Time Type Description Signal Details
2021-03-17 15:30 ESTNewsHorizon Therapeutics completes acquisition of Viela BioN/A
2021-03-09 09:52 ESTNewsViela Bio Is A Good Fit For Horizon TherapeuticsN/A
2021-03-04 02:06 ESTFinancialsCompany financials have been released.Neutral
2021-03-02 05:47 ESTNewsVIELA BIO EPS beats by $0.12, beats on revenueN/A
2021-03-02 02:23 ESTEarnings EstimateAn EPS average of -$0.70 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-02 02:23 ESTEarnings EstimateAn EPS average of -$2.35 is estimated for the 2022 year.Sell
2021-02-10 09:36 ESTAnalyst RatingThe Analyst Target Price has decreased from $53.25 to $53.Neutral
2021-02-03 09:43 ESTAnalyst RatingThe Analyst Target Price has increased from $53 to $53.25.Buy
2021-02-02 19:11 ESTNewsViela Bio soars 24% on being acquired by Horizon TherapeuticsN/A
2021-02-02 14:12 ESTAnalyst RatingThe Analyst Target Price has increased from $51.67 to $53.Buy
2020-12-04 18:24 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 23:45 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 13:50 ESTNewsViela Bio: Startup With A Head StartN/A
2020-11-18 03:34 ESTNewsViela Bio, Inc. 2020 Q3 - Results - Earnings Call PresentationN/A
2020-11-13 14:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $55.5 to $51.67.Neutral
2020-11-12 06:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 06:40 ESTAnalyst RatingThe Analyst Target Price has decreased from $59.17 to $55.5.Neutral
2020-11-11 08:01 ESTNewsVIELA BIO EPS beats by $0.08, misses on revenueN/A
2020-11-11 08:01 ESTNewsViela Bio, Inc. (VIE) CEO Bing Yao on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-11 06:21 ESTEarnings EstimateAn EPS average of -$0.71 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-08 02:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 19:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-03 10:14 ESTAnalyst RatingThe Analyst Target Price has decreased from $60.5 to $59.17.Neutral
2020-10-30 16:26 ESTAnalyst RatingThe Analyst Target Price has decreased from $61.67 to $60.5.Neutral
2020-09-26 15:52 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 08:22 ESTFinancialsCompany financials have been released.Neutral
2020-09-16 08:21 ESTNewsViela Bio Inc (VIE) Investor Presentation - SlideshowN/A
2020-08-14 23:07 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 11:55 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:29 ESTNewsViela Bio, Inc. 2020 Q2 - Results - Earnings Call PresentationN/A
2020-08-14 06:53 ESTAnalyst RatingThe Analyst Target Price has decreased from $63.17 to $61.67.Neutral
2020-08-13 23:10 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 07:29 ESTNewsVIELA BIO EPS beats by $0.32N/A
2020-08-13 07:29 ESTNewsViela Bio, Inc. (VIE) CEO Bing Yao on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-06 15:34 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 19:44 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 07:43 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 23:57 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 17:04 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 15:33 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 20:24 ESTFinancialsCompany financials have been released.Neutral
2020-07-20 18:57 ESTAnalyst RatingThe Analyst Target Price has increased from $63 to $63.17.Buy
2020-07-09 11:45 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 19:25 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 03:16 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 15:19 ESTFinancialsCompany financials have been released.Neutral
2020-06-16 21:14 ESTNewsViela Bio Gets Approval And Other News: The Good, Bad And Ugly Of BiopharmaN/A
2020-06-15 02:56 ESTAnalyst RatingThe Analyst Target Price has increased from $62 to $63.Buy
2020-06-14 07:28 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 09:02 ESTFinancialsCompany financials have been released.Neutral

About Viela Bio, Inc (VIE):

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; and which is in Phase III trials for patients with myasthenia gravis and IgG4-related diseases, as well as in Phase II trial for kidney transplant desensitization. It is also developing VIB4920 that is in Phase II trial for kidney transplantation rejection and rheumatoid arthritis, as well as in Phase IIb trial for sjögren's syndrome; and VIB7734, which is in Phase Ib trial for cutaneous lupus erythematosus, in Phase I trial for COVID-19-related acute lung injury, and a planned Phase II tria for systemic lupus erythematosus. The company's pre-clinical research and development product candidates include VIB1116 to decrease the number and function of antigen-presenting dendritic cells; and a mAb cytokine fusion protein to inhibit inflammatory responses. Viela Bio, Inc. has a strategic collaboration with Hansoh Pharmaceutical Group Company Limited and Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in China, Hong Kong, Macau, Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was incorporated in 2017 and is headquartered in Gaithersburg, Maryland.

VIE Quotes by TradingView

See Advanced Chart

General

  • Name Viela Bio, Inc
  • Symbol VIE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 170
  • Fiscal Year EndDecember
  • IPO Date2019-10-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.vielabio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 241.55
  • Price/Book (Most Recent Quarter) 7.74
  • Enterprise Value Revenue 218.15
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.72
  • Next Year EPS Estimate -$1.89
  • Next Quarter EPS Estimate -$0.75
  • Operating Margin -1321%
  • Return on Assets -24%
  • Return on Equity -41%
  • Revenue 11.65 million
  • Earnings Per Share -$78.90
  • Revenue Per Share $0.22
  • Gross Profit 9.61 million
  • Quarterly Earnings Growth -68.9%
View More

Highlights

  • Market Capitalization 2.91 billion
  • EBITDA -59735000
  • Analyst Target Price $53
  • Book Value Per Share -$293.22
View More

Share Statistics

  • Shares Outstanding 54.95 million
  • Shares Float 22.91 million
  • % Held by Insiders 5508%
  • % Held by Institutions 47.17%
  • Shares Short 1.92 million
  • Shares Short Prior Month 2.12 million
  • Short Ratio 1.09
  • Short % of Float 8%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • 52 Week High $62.69
  • 52 Week Low $22.28
  • 50 Day Moving Average 51.41
  • 200 Day Moving Average 38.47
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Viela Bio, Inc (VIE) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Viela Bio, Inc (VIE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$9.34 million-$0.60-$0.7014.29%
2020-09-302020-11-10$N/A-$0.69-$0.769.41%
2020-06-302020-08-12$N/A-$0.74-$1.0831.27%
2020-03-312020-05-13$N/A-$0.80-$0.73-9.1%
2019-12-312020-03-25$30 million-$0.23-$0.4751.7%
2019-09-302019-11-14$N/A-$1.17-$2.2748.6%

Viela Bio, Inc (VIE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Viela Bio, Inc (VIE) Chart:

Viela Bio, Inc (VIE) News:

Below you will find a list of latest news for Viela Bio, Inc (VIE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Viela Bio, Inc (VIE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Viela Bio, Inc (VIE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120038741/0001209191-20-038741-index.htm
2020-04-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1734517/000000000020003362/0000000000-20-003362-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1734517/000031506620001294/0000315066-20-001294-index.htm
2020-06-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1734517/000031506620001596/0000315066-20-001596-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924319024842/0000899243-19-024842-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924319024843/0000899243-19-024843-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924319025199/0000899243-19-025199-index.htm
2019-10-093/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924319025368/0000899243-19-025368-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924319025369/0000899243-19-025369-index.htm
2020-01-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924320001241/0000899243-20-001241-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924320001245/0000899243-20-001245-index.htm
2020-01-293/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924320002302/0000899243-20-002302-index.htm
2020-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924320002306/0000899243-20-002306-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000089924320015826/0000899243-20-015826-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1734517/000090266420001198/0000902664-20-001198-index.htm
2020-04-15DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1734517/000095012320003342/0000950123-20-003342-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919053627/0001104659-19-053627-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919053629/0001104659-19-053629-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919053630/0001104659-19-053630-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919053631/0001104659-19-053631-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919053737/0001104659-19-053737-index.htm
2019-10-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919054491/0001104659-19-054491-index.htm
2019-10-17SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1734517/000110465919054500/0001104659-19-054500-index.htm
2019-10-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919056270/0001104659-19-056270-index.htm
2019-10-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919056272/0001104659-19-056272-index.htm
2019-10-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919056278/0001104659-19-056278-index.htm
2019-10-253/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919056279/0001104659-19-056279-index.htm
2019-10-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465919056280/0001104659-19-056280-index.htm
2020-01-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1734517/000110465920008544/0001104659-20-008544-index.htm
2020-02-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1734517/000110465920011021/0001104659-20-011021-index.htm
2020-06-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1734517/000110465920070846/0001104659-20-070846-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465920071032/0001104659-20-071032-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465920071033/0001104659-20-071033-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000110465920071034/0001104659-20-071034-index.htm
2019-10-02S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1734517/000119312519260948/0001193125-19-260948-index.htm
2019-10-04424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1734517/000119312519261960/0001193125-19-261960-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312519263816/0001193125-19-263816-index.htm
2019-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312519264785/0001193125-19-264785-index.htm
2019-10-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1734517/000119312519266807/0001193125-19-266807-index.htm
2019-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312519310892/0001193125-19-310892-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520005419/0001193125-20-005419-index.htm
2020-03-25S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1734517/000119312520085171/0001193125-20-085171-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520128827/0001193125-20-128827-index.htm
2020-05-04DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1734517/000119312520132404/0001193125-20-132404-index.htm
2020-05-04DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1734517/000119312520132412/0001193125-20-132412-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520141629/0001193125-20-141629-index.htm
2020-05-26S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1734517/000119312520150799/0001193125-20-150799-index.htm
2020-05-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1734517/000119312520150846/0001193125-20-150846-index.htm
2020-05-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1734517/000119312520150849/0001193125-20-150849-index.htm
2020-05-29POS EXPost-effective amendment adding exhibits to registration statement [Rule 462(d)]https://www.sec.gov/Archives/edgar/data/1734517/000119312520155033/0001193125-20-155033-index.htm
2020-05-29424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1734517/000119312520155036/0001193125-20-155036-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520166885/0001193125-20-166885-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520174144/0001193125-20-174144-index.htm
2020-06-198-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520174151/0001193125-20-174151-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520217670/0001193125-20-217670-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520246211/0001193125-20-246211-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000119312520286844/0001193125-20-286844-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120016143/0001209191-20-016143-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120016146/0001209191-20-016146-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120016155/0001209191-20-016155-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120016160/0001209191-20-016160-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120016169/0001209191-20-016169-index.htm
2020-05-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120026669/0001209191-20-026669-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120038485/0001209191-20-038485-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120038489/0001209191-20-038489-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120038491/0001209191-20-038491-index.htm
2020-06-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1734517/000120919120038741/0001209191-20-038741-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000156459019043518/0001564590-19-043518-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1734517/000156459019043522/0001564590-19-043522-index.htm
2020-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1734517/000156459020012838/0001564590-20-012838-index.htm
2020-03-2510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1734517/000156459020012848/0001564590-20-012848-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1734517/000156459020025090/0001564590-20-025090-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1734517/000156459020039712/0001564590-20-039712-index.htm
2019-10-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1734517/999999999519002224/9999999995-19-002224-index.htm
2020-05-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1734517/999999999520001263/9999999995-20-001263-index.htm

Viela Bio, Inc (VIE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Viela Bio, Inc (VIE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 5508%
Institutional Ownership: 4717%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-07PLC ASTRAZENECA10% Share HolderBuy425,000.0019.008,075,000.0014,650,334.00https://www.sec.gov/Archives/edgar/data/1734517/000089924319025369/0000899243-19-025369-index.htm
2020-01-27William RagatzVP, Head of CommercialBuy16,250.005.2284,825.0016,250.00https://www.sec.gov/Archives/edgar/data/1734517/000089924320002306/0000899243-20-002306-index.htm
2019-10-07Andreas WickiDirectorBuy500,000.0019.009,500,000.001,750,000.00https://www.sec.gov/Archives/edgar/data/1734517/000110465919053627/0001104659-19-053627-index.htm
2020-06-05Edward HuDirectorSell9,000.0044.18397,620.00208,059.00https://www.sec.gov/Archives/edgar/data/1734517/000089924320015826/0000899243-20-015826-index.htm
2019-10-07Xiaomeng TongDirectorBuy300,000.0019.005,700,000.00300,000.00https://www.sec.gov/Archives/edgar/data/1734517/000110465919053631/0001104659-19-053631-index.htm
2019-10-08Xiaomeng TongDirectorBuy36,091.0021.83787,722.1736,091.00https://www.sec.gov/Archives/edgar/data/1734517/000110465919053737/0001104659-19-053737-index.htm
2019-10-07Xiaomeng TongDirectorSell36,091.0022.18800,501.9936,091.00https://www.sec.gov/Archives/edgar/data/1734517/000110465919053737/0001104659-19-053737-index.htm
2020-06-05Edward HuDirectorSell171,000.0044.187,554,780.003,953,118.00https://www.sec.gov/Archives/edgar/data/1734517/000089924320015826/0000899243-20-015826-index.htm
2020-06-05Yanling CaoDirectorSell360,000.0047.0016,920,000.008,322,353.00https://www.sec.gov/Archives/edgar/data/1734517/000110465920071032/0001104659-20-071032-index.htm
2020-06-05Meadow Ltd Boundless10% Share HolderSell360,000.0047.0016,920,000.008,622,353.00https://www.sec.gov/Archives/edgar/data/1734517/000110465920071034/0001104659-20-071034-index.htm
2020-06-05Xiaomeng TongDirectorSell360,000.0047.0016,920,000.008,622,353.00https://www.sec.gov/Archives/edgar/data/1734517/000110465920071033/0001104659-20-071033-index.htm